The field of RNA therapeutics has expanded incredibly in the past 30 years, and mRNA-based COVID-19 vaccines were just the start.
Clinical trials of an mRNA vaccine have begun, and researchers expect broadly positive outcomes in the fight against the widespread illness.
Despite the often-divisive discussions leading up to this state election, the next state parliament should focus on developing community cohesion in public health.
Unequal access to the COVID-19 vaccine fuelled calls for a patent waiver, but any major change needs to ensure a better outcome for developing economies.
Monash University is No.1 in the world for pharmacy and pharmacology, but what does that mean, and how are the university rankings calculated?
The case is growing stronger for COVID-19 vaccine mixing-and-matching, with recent data showing high efficacy and protection against SARS-CoV-2 virus strains.
Community pharmacies and pharmacists are important resources in Australia’s vaccine rollout, and right now they’re being under-utilised.
The rare blood-clotting issues associated with the Astra-Zeneca vaccine have recently made headlines, but it's too early to say whether it will increase overall vaccine hesitancy.
Dr Harry Al-Wassiti, Research Fellow at the Monash Institute of Pharmaceutical Sciences (MIPS), answers the questions about the jab that's on everyone's mind.
We'll struggle to find a vaccine that works perfectly for people who need it most, despite what the headlines say is coming in 2021.
Early analysis suggests Pfizer's COVID-19 vaccine has an efficacy of more than 90%, but more data is still needed.
A behind-the-scenes look at the two vaccine candidates being developed by Monash University and the Doherty Institute.
Dr Harry Al-Wassiti is now part of a Monash research team striving to find a COVID-19 vaccine, but his path has been far from easy.
How likely is it that we'll have a relatively quick fix for COVID-19, and what are the hurdles?
Dummy text
